We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abcam Plc | LSE:ABC | London | Ordinary Share | GB00B6774699 | ORD 0.2P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,226.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,240.00 | 1,246.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 1,226.00 | GBX |
Abcam (ABC) Share Charts1 Year Abcam Chart |
|
1 Month Abcam Chart |
Intraday Abcam Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/1/2023 | 08:47 | Welcome | 424 |
| 15/12/2022 | 16:38 | ABCAM with Charts & News | 239 |
| 08/9/2022 | 07:49 | testfollow | 3 |
| 19/11/2017 | 20:07 | Investing ? Start with your ABC's | 703 |
| 03/8/2017 | 10:31 | Abcam | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/12/2022 16:38 by bathcoup Sorry for the typo, thanks for correcting me. It was a last minute decision. BTW the shares had been held outside ISA; I bought 3,000 shares at 244p (before 1:5 split) for our joint account in early 2006. At that time AIM stocks weren't allowed in ISA's. I started unloading them a few years ago. Now I'm done with ABC. |
Posted at 28/11/2022 16:49 by lord loads of lolly jeffian - me neither. Nothing seems to have been reported today. Maybe it's anticipation of a possible uptick once dual listing ends? Whilst 13 Dec is the last official AIM trading day, my broker has said ABC shares will start being migrated across on 1 Dec. So the last date for me to trade them on AIM is 30 Nov. If they go up much more between now & then, I'll be following your lead. |
Posted at 28/10/2022 11:23 by lord loads of lolly jeffian - agreed, ISA value will go down, BUT non-ISA account will rise by the same value. So overall impact is nil. Except, that you'll no longer be exempt from capital gains tax on your Abcam holding. I don't think inheritance tax relief applied on Abcam shares held within an ISA, as they've been dual listed for some time, which I believe negates AIM IHT relief. Abcam's desire to delist from AIM appears short-sighted to me and NOT in the best interest of UK holders. Any uplift from an exclusive Nasdaq listing will likely soon fizzle out. So their proposal really just makes the shares more cumbersome & expensive for UK holders to trade. If the Nasdaq rallies again within the next couple of years & Abcam shares rise with it, I'll be looking to exit altogether before any CGT becomes liable. Presumably the starting valuation for CGT purposes will be ABC's share price on day 1 of conversion? |
Posted at 27/10/2022 16:53 by jeffian I realise I'm talking to myself here but IF anyone is lurking and in the same boat, the situation (at least, with HL) is that if you do wish to keep an investment in ABC and convert your shares to ADS's, any held in an ISA will be transferred out into your unprotected share account. In that event, the value of those shares will be lost to the ISA (i.e. the total value of the ISA account will be diminished by the equivalent amount). The only way to retain the value of the ISA is to sell those shares, re-purchase the equivalent amount in the unprotected share account and then accept the transfer to ADS's.I have voted against the Resolution to delist, to be held on 11 November, but if it gets carried, the shares can be traded up to 13 December to enable the actions mentioned above. Edit: Crossover post, lll. Nice to know there is life on Mars! Yes, seems we are saying the same, but note that if you allow the platform to transfer the shares from your ISA to your trading account, you will lose that value in the ISA. |
Posted at 27/10/2022 16:50 by lord loads of lolly jefflan - I use a different broker who says they can't be held in an ISA post-conversion, but can be held & traded as normal in a standard share dealing account. So I guess the main downside is a loss of any capital gains protection. Not sure AIM IHT protection was still in force anyway, given Abcam's previous joint UK/US listing. |
Posted at 21/10/2022 22:39 by jeffian Clearly not a well-followed share on here then! |
Posted at 16/6/2022 12:39 by don carter Thanks for those valid comments Lord loads & jeffian. I think I had got too attached to ABC, having been in them for a long time and having lived close to Cambridge Science Park, also for a long time. I'm selling my very small residual holding today. |
Posted at 13/9/2021 14:17 by lord loads of lolly I also find the 3% markdown in ABC's share price odd, given the higher reported revenues & GM%. Perhaps it's those D&A costs that spooked innvestors? Or the fact the share price had risen quite steeply pre-results, creating a classic case of "buy the rumour, sell the news". Any other ideas? |
Posted at 01/6/2021 15:09 by bulltradept The IC has it as a holdAbcam hampered by research shut-downs However, the group has maintained its longer-term targets, while putting the dividend on ice September 14, 2020 By Harriet Clarfelt Antibodies have been a much-discussed topic since the outbreak of Covid-19, playing a central role in testing and treatment programmes. These blood proteins, which develop in response to infection, can show whether a person has already had a disease – helping authorities to monitor the spread of infection. Scientists are also investigating whether antibody therapy can aid patients who are still sick. IC TIP: Hold at 1366p ABC:LSE Abcam PLC 1mth Today change -3.04%Price (GBP) 1,373.00 But the buzz around antibodies and coronavirus forms just one part of a vast global research landscape. And aside from work to target the pandemic, most laboratories were shuttered when lockdowns took hold. Thus, while Abcam (ABC) saw some benefit from the use of its products in virus studies during the 12 months to June, this was tempered by reduced demand elsewhere. The group – which makes and sells protein-research tools, including antibodies, to the life sciences sector – reported revenues of £260m; flat year-on-year, or down 1.4 per cent at constant currencies. Abcam explained that timings “correlated strongly” with the phasing of global government shutdowns. While the first half of the year saw 10.8 per cent sales growth, the second half saw a proportionate decline. However, on a more positive note, the group has not observed any big changes to its underlying customer base. What’s more, management observed that by June 2020, demand was roughly in line with levels seen the previous summer. That recovery goes some way to explain the group’s reiteration of its 2023/24 targets and its associated investment plans. Bosses are aiming for revenues of £450-500m, an adjusted operating margin of more than 30 per cent and a return on capital employed (ROCE) of over 18 per cent. The effects of such an expenditure strategy were evident at the interim mark. When combined with the blow dealt by Covid-19, adjusted costs rose by more than a third to £136m – higher than Peel Hunt’s estimate of £111m. In turn, adjusted operating profits halved to £44.5m, on a margin of 17.1 per cent – down from 32.2 per cent. The broker noted that the “small miss” on costs may have read-across for anticipated expenses in FY2021. The statutory story was rather more dramatic, with pre-tax profits plunging by 85 per cent to £8.4m. This reflected a number of dampeners – the largest of which was the £14.9m write-down of certain technologies tied to Abcam’s acquisition of AxioMx five years ago. Abcam noted that while this is proving commercial feasibility, it has yet to see usage at a scale to support its asset value. Other factors at play included system improvement costs, and spending on the purchase of Expedeon’s proteomics (protein study) and immunology businesses. Meanwhile, in a bid to boost its flexibility around capital allocation, Abcam has put the dividend on ice, with a view to injecting more money into growth opportunities. At the same time, and in the same vein, the group is moving forward with plans to pursue a secondary listing on America’s Nasdaq index. Little wonder, perhaps; more than two-fifths of revenues stem from the US. The improving trends towards the end of Abcam’s fiscal year have continued into the current period, with more labs reopening - and the maintenance of its longer-term growth ambitions is encouraging. Chief executive Alan Hirzel also noted that Covid-19’s broad impact on the immune response has meant that “all kinds of new questions [are] being raised about immunology”. Abcam has accelerated its investments in this research area, “knowing that Covid is likely to spark long-term interest in that field”. Still, for now the crisis continues, and it is impossible to know whether restrictions will be reintroduced – meaning that the group has not offered up full-year guidance. A forward price/earnings multiple of more than 70 times (based on Numis’s projections) keeps us neutral. Last IC view: Hold, 1,143p, 09 Mar 2020 |
Posted at 10/9/2019 10:25 by buywell3 abc share price imo at bottom support line as i keydyor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
